DDInter948 DDInter969
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approval on 25 March 2011.
Ipilimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Budesonide
Ipilimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enfortumab vedotin
Ipilimumab {u} may lead to a major life threatening interaction when taken with {v} Apixaban
Ipilimumab {u} may lead to a major life threatening interaction when taken with {v} Ardeparin
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Budesonide
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Ipilimumab may lead to a major life threatening interaction when taken with Apixaban
Ipilimumab may lead to a major life threatening interaction when taken with Ardeparin